7 February 2024 in World Neurosurgery
FVFernando De Nigris Vasconcellos
Fernando De Nigris Vasconcellos
LRLeonardo Rangel-Castilla
+6
17 July 2026 in The Lancet Regional Health - Americas
Type 2 diabetes (T2D) is a heterogeneous disease and a major public health concern in low- and middle-income countries (LMICs). To address this heterogeneity, several subgroup classification frameworks have been proposed. Among them, the most widely used is the data-driven classification proposed by Ahlqvist et al., which includes severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD). However, reproducing this framework is limited by the need for specialized measurements of beta-cell function and insulin resistance, which are not routinely available in most clinical or epidemiological settings in LMICs. To overcome these barriers, we derived a classification algorithm to reproduce these diabetes subgroups. Here, we present a four-step roadmap in which this framework may help characterize T2D heterogeneity across Mexico, potentially guide pathophysiology-oriented treatment strategies, support public health monitoring, and enhance our understanding of T2D heterogeneity to improve diabetes care in our country.
21 August 2026 in medRxiv
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
MGMauricio Gonzalez-Arias
DADiego Araiza-Garaygordobil
Diego Araiza-Garaygordobil
Body mass index (BMI) alone may underestimate clinically relevant obesity because it does not capture central fat distribution. We compared obesity prevalence in Mexico using BMI-only criteria, adiposity-confirmed criteria, and the clinical obesity definition proposed by the Lancet Diabetes and Endocrinology Commission. We conducted a population-based, cross-sectional study of 13,160 adults aged 18 years or older who participated in the 2018-2019 Mexican National Health and Nutrition Survey (ENSANUT). Obesity prevalence was estimated through survey-weighted analyses that accounted for the complex sampling design. The weighted prevalence of obesity based on BMI was 34.5% (95% CI, 33.1-35.9), while 30.9% (95% CI, 29.6-32.2) met criteria for clinical obesity. One quarter of individuals with clinical obesity had a BMI under 30 kg/m 2 , a phenotype more common among older adults. Half of adults with a BMI under 30 kg/m 2 showed elevated central adiposity. BMI alone underestimates clinically relevant obesity in Mexican adults. Adding waist-based measurements could improve the identification of individuals with excess fat and metabolic risk, both in clinical settings and population monitoring.
31 October 2026 in Clinical Cardiology
Background: Patients with type 2 diabetes mellitus (T2DM) who experience acute coronary syndromes (ACS) remain at high risk for recurrent ischemic events despite secondary prevention. Lipoprotein(a) [Lp(a)] contributes to residual cardiovascular risk, but its prognostic impact on recurrent myocardial infarction (MI) and repeat revascularization in diabetic patients after ACS or percutaneous coronary intervention (PCI) remains unclear. Hypothesis: We hypothesized that elevated Lp(a) is associated with increased risk of recurrent MI and repeat coronary revascularization in patients with diabetes after ACS or PCI. Methods: We conducted a PRISMA‐guided systematic review and meta‐analysis. PubMed, EBSCOhost, and Cochrane Library were searched for studies evaluating Lp(a) and recurrent cardiovascular outcomes in patients with diabetes after ACS or PCI. Observational studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) were included. Pooled HRs were calculated using random‐effects models. Results: Seven studies comprising 7887 patients with diabetes and prior ACS or PCI were included. Elevated Lp(a) was associated with increased risk of recurrent MI (pooled HR 2.17, 95% CI 1.02–4.62; I 2 = 75%) but not repeat coronary revascularization (pooled HR 1.68, 95% CI 0.79–3.57; I 2 = 78%). Conclusions: Elevated Lp(a) was associated with increased risk of recurrent MI in patients with diabetes after ACS or PCI. Findings should be interpreted considering the observational study designs, substantial heterogeneity, and limited evidence for repeat revascularization. These findings support Lp(a) as a contributor to residual cardiovascular risk and its potential role in post‐ACS risk stratification. Trial Registration: This study was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420261296821).